Cellular Hypertrophy and Hyperplasia in Disease

Core Idea

Hypertrophy is increase in cell size through accumulation of contractile proteins and organelles; hyperplasia is increase in cell number through proliferation. Both represent compensatory responses to increased workload but can become pathologic if uncontrolled, leading to organ dysfunction.

Explainer

The key to understanding hypertrophy versus hyperplasia is recognizing that not all cells can divide. From your study of the cell cycle, you know that progression through G1, S, G2, and M requires growth factor signaling, adequate nutrients, and CDK-cyclin complexes to be active. Permanent cells — neurons, cardiac myocytes, and skeletal muscle fibers — have largely exited the cell cycle and cannot proliferate in response to injury or increased demand. Stable (quiescent) cells — hepatocytes, smooth muscle cells, fibroblasts — are in G0 but can re-enter the cycle when stimulated. Labile cells — intestinal epithelium, bone marrow precursors, skin keratinocytes — cycle continuously. This division determines which adaptive response is available: permanent cells can only hypertrophy; labile and stable cells can do both.

Hypertrophy is the increase in cell size without cell division, driven by increased protein synthesis exceeding protein degradation. The cardiac myocyte is the paradigm case. When left ventricular afterload increases — due to hypertension or aortic stenosis — myocytes synthesize more contractile proteins (actin, myosin heavy chains) and add more sarcomeres. The result is a thicker, heavier ventricle that can generate more force. Growth factor signaling (IGF-1, angiotensin II, endothelin) activates the PI3K/Akt/mTOR pathway, which drives ribosomal biogenesis and protein translation. In the early compensatory phase, hypertrophy maintains cardiac output. But sustained hypertrophy is maladaptive: the enlarged myocyte outgrows its capillary supply, mitochondrial density falls relative to cell volume, and the tissue becomes stiff, predisposing to diastolic dysfunction, arrhythmia, and eventually heart failure.

Hyperplasia is increase in cell number through mitosis, available only to cells capable of re-entering the cell cycle. From your cell cycle knowledge, you know this requires cyclin D upregulation, Rb phosphorylation, and E2F transcriptional activation of S-phase genes. Growth factor receptors — EGFR, PDGFR, estrogen receptor — drive this process in hormone-responsive or injury-stimulated tissues. Physiologic hyperplasia is beneficial: bone marrow hyperplasia in response to anemia, compensatory liver hyperplasia after partial hepatectomy. Pathologic hyperplasia — endometrial hyperplasia driven by unopposed estrogen, prostatic hyperplasia, or thyroid goiter — occurs when the proliferative signal is chronically elevated. Pathologic hyperplasia is clinically important because, unlike neoplasia, it retains normal growth-control mechanisms and regresses when the stimulus is removed; but it creates a substrate of increased cell number in which subsequent mutations can more easily accumulate, increasing cancer risk.

The boundary between adaptation and pathology is defined by control: hypertrophy and hyperplasia become pathologic when growth is disproportionate to the functional demand, when the structural changes impair organ function rather than enhance it, or when proliferative control is lost. The final step toward malignancy — which neither hypertrophy nor hyperplasia represents — occurs when cells acquire autonomous growth-promoting mutations and lose the ability to stop. Understanding where on this continuum a given cellular change sits is fundamental to pathologic diagnosis.